Identifying post-menopausal women at elevated risk for epithelial ovarian cancer

Gynecologic Oncology

Volumn 139, Issue 2, 2015, Pages 253-260

  Urban, Nicole ^a   Hawley, Sarah ^a   Janes, Holly ^a   Karlan, Beth Y ^b   Berg, Christine D ^c   Drescher, Charles W ^a   Manson, Joann E ^d   Palomares, Melanie R ^e   Daly, Mary B ^f   Wactawski Wende, Jean ^g   O'Sullivan, Mary J ^h   Thorpe, Jason ^a   Robinson, Randal D ⁱ   Lane, Dorothy ^j   Li, Christopher I ^a   Anderson, Garnet L ^a  

^a USA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j STONY BROOK UNIVERSITY   (United States)

more..

Author keywords

CA125; HE4; Ovarian cancer; Risk prediction

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; ORAL CONTRACEPTIVE AGENT; PROTEIN; TALC; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CLASSIFIER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CARCINOMA; POSTMENOPAUSE; PRIORITY JOURNAL; UTERINE TUBE; UTERINE TUBE LIGATION; VERY ELDERLY; BREAST FEEDING; BREAST NEOPLASMS; CASE CONTROL STUDY; ESTROGEN THERAPY; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PARITY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UTERINE TUBE STERILIZATION; UTILIZATION;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST FEEDING; BREAST NEOPLASMS; CA-125 ANTIGEN; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PARITY; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROTEINS; RISK ASSESSMENT; RISK FACTORS; STERILIZATION, TUBAL; TALC;

EID: 84952631744     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.08.024     Document Type: Article

References (42)

1. M.R. Andersen, B.A. Goff, K.A. Lowe, N. Scholler, L. Bergan, C.W. Drescher, and et al. Use of a symptom index, CA125, and HE4 to predict ovarian cancer Gynecol. Oncol. 116 3 2010 378 383 (Epub 2009/12/01)
2. S.J. Ramus, and S.A. Gayther The contribution of BRCA1 and BRCA2 to ovarian cancer Mol. Oncol. 3 2 2009 138 150 (Epub 2009/04/23)
3. A. Antoniou, P. Pharoah, S. Narod, and et al. Average risk of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies Am. J. Hum. Genet. 72 5 2003 1117 1130
4. T.R. Rebbeck, N.D. Kauff, and S.M. Domchek Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers J. Natl. Cancer Inst. 101 2 2009 80 87 (Epub 2009/01/15)
5. H.D. Nelson, R. Fu, K. Goddard, J.P. Mitchell, L. Okinaka-Hu, M. Pappas, and et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the US Preventive Services Task Force Recommendation. Rockville (MD) 2013
6. W.H. Parker, D. Shoupe, M.S. Broder, Z. Liu, C. Farquhar, and J.S. Berek Elective oophorectomy in the gynecological patient: when is it desirable? Curr. Opin. Obstet. Gynecol. 19 4 2007 350 354 (Epub 2007/07/13)
7. J.N. McAlpine, G.E. Hanley, M.M. Woo, A.A. Tone, N. Rozenberg, K.D. Swenerton, and et al. Opportunistic salpingectomy: uptake, risks and complications of a regional initiative for ovarian cancer prevention Am. J. Obstet Gynecol. 2014 (Epub 2014/01/15)
8. A.K. Folkins, E.A. Jarboe, M.H. Roh, and C.P. Crum Precursors to pelvic serous carcinoma and their clinical implications Gynecol. Oncol. 113 3 2009 391 396 (Epub 2009/02/25)
9. J. Dietl, J. Wischhusen, and S.F. Hausler The post-reproductive fallopian tube: better removed? Hum. Reprod. 26 11 2011 2918 2924 (Epub 2011/08/19)
10. M. Morelli, R. Venturella, R. Mocciaro, A. Di Cello, E. Rania, D. Lico, and et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: Primum non nocere Gynecol. Oncol. 2013 (pii: S0090-8258(13):00178-9, Epub 2013/04/06)
11. C.B. Gilks, and D. Miller Opportunistic salpingectomy for women at low risk for development of ovarian carcinoma: the time has come Gynecol. Oncol. 129 3 2013 443 444 (Epub 2013/05/15)
12. J.S. Berek, E. Chalas, M. Edelson, D.H. Moore, W.M. Burke, W.A. Cliby, and et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer Obstet. Gynecol. 116 3 2010 733 743 (Epub 2010/08/25)
13. N.D. Kauff, N. Mitra, M.E. Robson, K.E. Hurley, S. Chuai, D. Goldfrank, and et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families J. Natl. Cancer Inst. 97 18 2005 1382 1384
14. K.A. Metcalfe, A. Finch, A. Poll, D. Horsman, C. Kim-Sing, J. Scott, and et al. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation Br. J. Cancer 100 2 2009 421 425 (Epub 2008/12/18)
15. G.L. Anderson, M.W. McIntosh, L. Wu, M. Barnett, G. Goodman, J.D. Thorpe, and et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study J. Natl. Cancer Inst. 102 1 2010 26 38
16. B.B.J. Hermsen, S. von Mensdorff-Pouilly, J. Berkhof, P.J. van Diest, J.J.P. Gille, F.H. Menko, and et al. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer J. Clin. Oncol. 25 11 2007 1383 1389
17. M.A. Karlsen, N. Sandhu, C. Hogdall, I.J. Christensen, L. Nedergaard, L. Lundvall, and et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass Gynecol. Oncol. 127 2 2012 379 383 (Epub 2012/07/28)
18. R.G. Moore, M.C. Miller, M.M. Steinhoff, S.J. Skates, K.H. Lu, G. Lambert-Messerlian, and et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders Am. J. Obstet. Gynecol. 206 4 2012 351 (e1-8, Epub 2012/01/31)
19. S.S. Buys, E. Partridge, A. Black, C.J. Johnson, L. Lamerato, C. Isaacs, and et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial JAMA 305 22 2011 2295 2303
20. D.W. Cramer, R.C. Bast Jr., C.D. Berg, E.P. Diamandis, A.K. Godwin, P. Hartge, and et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens Cancer Prev. Res. (Phila.) 4 3 2011 365 374
21. C.S. Zhu, P.F. Pinsky, D.W. Cramer, D.F. Ransohoff, P. Hartge, R.M. Pfeiffer, and et al. For the PLCO Project Team. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer Cancer Prev. Res. (Phila.) 4 3 2011 375 383
22. N. Urban, J.D. Thorpe, L.A. Bergan, R.M. Forrest, A.V. Kampani, N. Scholler, and et al. Potential role of HE4 in multimodal screening for epithelial ovarian cancer J. Natl. Cancer Inst. 103 21 2011 1630 1634 (Epub 2011/09/16)
23. A.F. Vitonis, L. Titus-Ernstoff, and D.W. Cramer Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy Obstet. Gynecol. 117 5 2011 1042 1050 (Epub 2011/04/08)
24. L.S. Morch, E. Lokkegaard, A.H. Andreasen, S.K. Kjaer, and O. Lidegaard Hormone therapy and different ovarian cancers: a national cohort study Am. J. Epidemiol. 175 12 2012 1234 1242 (Epub 2012/04/21)
25. V. Koskela-Niska, H. Lyytinen, A. Riska, E. Pukkala, and O. Ylikorkala Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy - a nationwide study Climacteric 16 1 2013 48 53 (Epub 2012/05/30)
26. V. Koskela-Niska, E. Pukkala, H. Lyytinen, O. Ylikorkala, and T. Dyba Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer - a population-based case control study from Finland Int. J. Cancer 133 7 2013 1680 1688 (Epub 2013/03/26)
27. G.L. Anderson Implementation of the Women's Health Initiative Study Design Ann. Epidemiol. 13 9 Suppl. 2003 S5 17
28. J.D. Curb, A. McTiernan, S.R. Heckbert, C. Kooperberg, J. Stanford, M. Nevitt, and et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative Ann. Epidemiol. 13 9 Suppl. 2003 S122 S128 (Epub 2003/10/25)
29. C.R. Morris, L. Liu, A.O. Rodriguez, R.D. Cress, and K. Snipes Epidemiologic features of borderline ovarian tumors in California: a population-based study Cancer Causes Control 24 4 2013 665 674 (Epub 2013/01/15)
30. R.J. Kurman, and C.L. Trimble The behavior of serous tumors of low malignant potential: are they ever malignant? Int. J. Gynecol. Pathol. 12 2 1993 120 127 (Epub 1993/04/01)
31. J.F. Leake, J.L. Currie, N.B. Rosenshein, and J.D. Woodruff Long-term follow-up of serous ovarian tumors of low malignant potential Gynecol. Oncol. 47 2 1992 150 158 Epub 1992/11/01
32. M.E. Sherman, P.J. Mink, R. Curtis, T.R. Cote, S. Brooks, P. Hartge, and et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis Cancer 100 5 2004 1045 1052 Epub 2004/02/26
33. M. McIntosh, and N. Urban A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker Biostatistics 4 1 2003 27 40
34. M. McIntosh, N. Urban, and B. Karlan Generating longitudinal screening algorithms using novel biomarkers for disease Cancer Epidemiol. Biomark. Prev. 11 2 2002 159 166
35. N. Urban, J.D. Thorpe, B.Y. Karlan, M.W. McIntosh, M.R. Palomares, M.B. Daly, and et al. Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer Cancer Epidemiol. Biomark. Prev. 21 11 2012 2087 2094 (Epub 2012/09/07)
36. S.J. Schonfeld, A. Berrington de Gonzalez, K. Visvanathan, R.M. Pfeiffer, and W.F. Anderson Declining second primary ovarian cancer after first primary breast cancer J. Clin. Oncol. 31 6 2013 738 743 (Epub 2013/01/04)
37. A. Obermair, D.R. Youlden, P.D. Baade, and M. Janda The impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy on survival in patients with a history of breast cancer - a population-based data linkage study Int. J. Cancer 134 9 2014 2211 2222 (Epub 2013/10/16)
38. SEER Cancer Statistics Review 1975-2011 National Cancer Institute. Bethesda, MD http://seer.cancer.gov/csr/1975-2011/browse-csr.php?sectionSEL=21&pageSEL=sect-21-table.16.html 2015 (cited 2015 4/7/15)
39. M.S. Piver Prophylactic oophorectomy: reducing the U.S. Death rate from epithelial ovarian cancer. A continuing debate Oncologist 1 5 1996 326 330 Epub 1996/01/01
40. A.N. Rosenthal, L. Fraser, R. Manchanda, P. Badman, S. Philpott, J. Mozersky, and et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule J. Clin. Oncol. 31 1 2013 49 57 (Epub 2012/12/06)
41. C.L. Pearce, D.O. Stram, R.B. Ness, D.A. Stram, L.D. Roman, C. Templeman, and et al. Population distribution of lifetime risk of ovarian cancer in the United States Cancer Epidemiol. Biomark. Prev. 24 4 2015 671 676 (Epub 2015/01/28)
42. C.B. Powell, E.M. Swisher, I. Cass, J. McLennan, B. Norquist, R.L. Garcia, and et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy Gynecol. Oncol. 129 2 2013 364 371 (Epub 2013/02/09)